Acadia Pharmaceuticals Inc. has been striving for several years to build out the label for its Parkinson’s psychosis drug Nuplazid (pimavanserin), and things took a turn for the better on 25 November when the company reported success in a 403-patient Phase II study of schizophrenia patients with negative symptoms.
The data follow a major setback in June, when the drug failed a Phase III study testing it for adjuvant...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)